Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary

February 13, 2020

NASDAQ US Health Care Biotechnology earnings 51 min

Earnings Call Speaker Segments

Holly Manning

executive
#1

Thanks, operator. Hello, everyone, and good morning. It's a pleasure to have you join Agios' conference call for the fourth quarter and full year 2019. Slides for today's call can be found in the Investors area of our site, agios.com. Joining me today with prepared comments are Dr. Jackie Fouse, who serves as our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Darrin Miles, our Senior Vice President of U.S. Commercial and Global Marketing; and Andrew Hirsch, our Chief Financial Officer and Head of Corporate Development. Prior to beginning, I want to remind all of you that certain statements we make today will contain forward-looking statements. Actual events and results might differ materially from those expressed or implied by any forward-looking statements because of various risks, uncertainties and other factors, including those described in the Risk Factors section of our most recent Form 10-Q filed with the SEC and any other filings we may make with the SEC. With that said, I'll hand the call over to Jackie.

Jacqualyn Fouse

executive
#2

Thanks, Holly. Morning, everyone, and thanks for being on the call for our Q4 2019 results. I became CEO at Agios 12 months ago, and back then, I felt thrilled about what this company does and how we can make a real difference for patients. Now, heading into 2020, I feel even more thrilled about where we stand. Over the past 12 months, I've listened to and learned from my colleagues, backed the delivery of a number of notable firsts for the company, and assessed how to build on what we've already achieved and sharpen our focus so we create value for patients and all of our stakeholders. My confidence is stronger than ever in the caliber of our science, how strong our team is, and our remarkable portfolio spanning preclinical, clinical, and commercial programs that is genuinely differentiated. That excitement and confidence led us to launch our 2025 strategic vision in January, where for the first time we shared what the company might look like as our portfolio advances over the coming 6 years. By the close of 2025, we anticipate having 4 marketed medicines, every one discovered and developed at Agios, producing at minimum $1 billion in product revenue from no fewer than 8 indications spanning our 3 focus areas: hematologic malignancies, solid tumors, and rare genetic diseases. We'll have 6 or more molecules in the clinic, 4 of them completely new molecules coming from our internal research discovery engine, and we will be cash flow positive during that 6-year window. This long-term vision rests on the foundation of what we achieved in 2019 along with our current clinical and late-stage preclinical programs. Within our base case plan, I also believe we have enormous optionality and a chance to potentially surpass our goals. Our steps along the road to 2025 are already in motion with an ambitious set of 2020 objectives across our malignant hematology, solid tumor, and rare genetic disease programs; in fact, this stands out as one of the most compelling elements of our 6-year vision. We have meaningful milestone events happening each year over the coming 6 years. My colleagues will go into our programs and objectives in greater detail shortly. Before I finish, I want to publicly welcome our new Chief Scientific Officer, Dr. Bruce Car, who came to Agios last month. Bruce, along with his scientific leadership team, will be guiding the next wave of programs from research into the clinic to help us reach our 2025 vision, and we're thrilled to have him with us during this pivotal time; we look forward to Bruce joining us on future results calls. With that, I'll hand the call over to Chris for our clinical and regulatory updates.

Chris Bowden

executive
#3

Appreciate that, Jackie. Our 2025 goals rest on a number of clinical programs, both early and late stage, that reach across blood cancers, solid tumors and rare genetic disorders, and during 2020 we intend to deliver meaningful advances in every one of those therapeutic areas. Let me begin with rare genetic diseases, where we anticipate several key milestones during 2020 for our PKR activation program covering 3 distinct hemolytic anemias. The first area we're focused on is pyruvate kinase deficiency, where mitapivat works by activating a mutated PKR enzyme and could become the first disease-modifying therapy for this chronic anemia, for which no approved treatment options exist at present. We have 2 pivotal studies of mitapivat underway in PK deficiency. ACTIVATE-T is being run in regularly transfused patients, while the ACTIVATE study involves patients who are not regularly transfused. Both studies have now closed enrollment, and we intend to report top line data before the year is out. On top of that, we're proceeding with our plan to investigate mitapivat in pediatric PK deficiency patients. Thanks to our regulatory interactions and advisory boards, we feel confident about our ability to move mitapivat forward in this patient population, and we anticipate launching a clinical trial in 2021. During 2019, we broadened the clinical use of mitapivat into thalassemia and sickle cell disease, where activating wild-type PKR may deliver therapeutic benefit. In December, we reported achieving proof-of-concept in the ongoing Phase II thalassemia study, in which treatment with mitapivat produced a hemoglobin response of at least 1 gram per deciliter in 7 of 8 evaluable patients. Further data from this study, including findings from patients with alpha thalassemia as well as beta thalassemia, will be submitted for presentation at the European Hematology Association Congress in June. We're actively working out a pivotal strategy for mitapivat in thalassemia, and we intend to finalize it before the year ends. For sickle cell disease, we're partnering with Dr. Swee Lay Thein at the National Institutes of Health on a proof-of-concept study under a cooperative research and development agreement. This study, which will enroll up to 25 patients, is designed to assess safety and tolerability, shifts in laboratory parameters such as reticulocytes and hemoglobin levels, pharmacokinetics and pharmacodynamic markers, including levels of 2,3-DPG and ATP, along with sickling in red blood cells. Enrollment is progressing well, and we expect Dr. Thein to submit data from this study for presentation at EHA. In addition to mitapivat, we've created a next-generation PKR activator, AG-946, and intend to file the investigational new drug application this quarter. After the IND clears, we'll launch a study in healthy volunteers during the second quarter. Turning to hematologic malignancies. Over the past several years we've moved quickly to secure U.S. approval for TIBSOVO monotherapy, an IDH1 mutant relapsed-refractory and frontline AML, while producing important data from the Phase I study combining TIBSOVO with standard of care frontline therapies. The upcoming stage for TIBSOVO's development centers on securing worldwide approvals for first-line combo regimens, and that should let us treat as many AML patients harboring an IDH1 mutation as possible. Patient accrual is still ongoing in two trials: the Phase III AGILE trial testing TIBSOVO alongside azacitidine, plus the HOVON 150 trial pairing TIBSOVO and IDHIFA with standard induction and consolidation chemo. Over in the EU, our day 120 responses for the TIBSOVO relapsed-refractory AML submission have been filed, and at this point we await the day 180 list of outstanding items from the European Medicines Association. Word came recently from the EMA that Celgene BMS pulled its IDHIFA marketing authorization application, since the single-arm Phase I trial failed to completely resolve the major objections the CHMP had raised in order to back a favorable benefit risk assessment within the proposed indication. Making TIBSOVO accessible to European patients is still what we're aiming for, and our MAA keeps progressing through the EMA review process. Beyond AML, TIBSOVO development is moving forward in myelodysplastic syndrome, and we just reopened the MDS cohort of the Phase I trial in IDH1 mutant hematologic malignancies. Trial size has been boosted to a maximum of 25 MDS patients, with enrollment completion anticipated by the end of the year. Breakthrough therapy designation was granted to TIBSOVO for this indication, and we aim to produce enough data from the enlarged Phase I arm to support a possible U.S. regulatory filing in MDS. Finally, patient enrollment continues in the Phase I trial of AG-636, our DHODH inhibitor for advanced lymphoma. By the end of the year, we intend to have adequate data to figure out what comes next for this program. Turning to solid tumors, during 2019 we demonstrated that IDH inhibition is useful for treating such tumors, thanks to positive results from the ClarIDHy Phase III trial of TIBSOVO in previously treated IDH1 mutant cholangiocarcinoma. Findings indicated that TIBSOVO cut the risk of disease progression or death by 63%, alongside meaningful improvement and landmark analyses for PFS at 6 and 12 months. Mature overall survival results from ClarIDHy should arrive in mid-2020, and we intend to file a supplemental new drug application containing this data by year-end. As mentioned back in January, our Phase III INDIGO trial of vorasidenib, the brain penetrant pan IDH inhibitor we're developing for low-grade glioma, kicked off at the close of 2019. Right now the team is concentrating on activating sites for this worldwide trial. AG-270, a MAT2A inhibitor, is our remaining solid tumor program, and it's presently under evaluation alongside standard of care taxanes across 2 arms of a Phase I trial — one for non-small cell lung cancer, the other for pancreatic cancer. Within the coming 2 years, we hope to collect enough clinical data across these 2 patient groups to determine whether the striking synergy between AG-270 and taxanes that we showed preclinically in these indications can be reproduced. At this point, I'll hand things over to Darrin so he can walk us through how our commercial side performed.

Darrin Miles

executive
#4

Thanks, Chris. I'm happy to walk through what we delivered in the fourth quarter of 2019, along with our first complete year of product revenue since the launch that happened in mid-2018. During Q4, TIBSOVO generated $20 million in net sales, which brought the full-year 2019 figure for TIBSOVO to $60 million. The quarter's growth came mainly from ongoing uptake in the relapsed-refractory setting and the frontline AML setting, plus further broadening of our distinct prescriber base, which rose 15% versus Q3. Findings from our market research keep indicating that regimens containing TIBSOVO rank as the top choice for patients newly diagnosed with AML and those in first relapse who carry an IDH1 mutation. As we look forward, our guidance for 2020 U.S. TIBSOVO net sales sits at $105 million to $115 million, and at the midpoint that works out to roughly an 80% gain compared with 2019. We anticipate further growth in the newly diagnosed setting as well as the relapsed-refractory setting. So far, the biggest factor behind revenue growth has been longer treatment duration, a trend we see across both AML labels. Even though our team doesn't promote it, about half of patients treated with TIBSOVO in both the newly diagnosed and relapsed-refractory groups receive it in combination, mostly alongside a hypomethylating agent. We expect that to keep helping average duration, and we think it will land near the 5-month mark as 2020 comes to an end. Now on to rare genetic disease. Our team is ramping up prelaunch activity ahead of a possible approval for mitapivat late next year. As we mentioned in January, we have already pinpointed roughly 1,000 PK deficient patients across the U.S. and EU5, and we're still focused on driving patient identification, raising disease awareness, and improving testing for this serious chronic anemia. Our existing global medical affairs and marketing teams are behind this work. And as 2020 unfolds, we'll start assembling a modest field team to back our market development efforts. I'd like to thank the incredible team at Agios, who served as the driving force behind our 2019 success and built the foundation that will let us support many more patients in 2020. With that, I'll hand the call to Andrew so he can go over our fourth quarter financials.

Andrew Hirsch

executive
#5

Thank you, Darrin. You can find our results for the fourth quarter and the full year in this morning's press release, and I'll walk through the highlights. Additional detail will appear in the 10-K we file next week. Fourth quarter total revenue came to $35 million, which brought full year 2019 total revenue to $118 million — that's an increase of $23.5 million over 2018. TIBSOVO product sales rose $46 million year-over-year, which was offset by lower collaboration revenue stemming from recognition of a Celgene milestone plus the CStone upfront payment, together totaling $27 million. Cost of sales was $287,000 in the fourth quarter and $1.3 million for full year 2019. Now to operating expenses. R&D came in at $106 million for the fourth quarter and $411 million for full year 2019, up $70 million versus full year 2018. That year-over-year R&D increase was mainly attributable to clinical trial activity for mitapivat in PK deficiency and thalassemia, start-up costs for the vorasidenib Phase III INDIGO study in low-grade glioma, along with required clinical pharmacology studies and companion diagnostic work, ongoing recruiting efforts in the TIBSOVO Phase III AGILE and HOVON frontline AML combination studies, and ongoing research efforts across our discovery platform programs. Selling, general and administrative expenses totaled $35 million in the fourth quarter and $132 million for full year 2019. That's an $18 million increase over full year 2018, primarily from greater investment in marketing activities as we prepare for the potential launch of mitapivat and from personnel costs tied to increased headcount supporting our growing operations. We closed the quarter with cash, cash equivalents and marketable securities of $718 million. We expect this cash balance, together with expected product revenue, royalties, and anticipated expense reimbursements under our collaboration and license agreements, but excluding any additional collaboration related payments, will fund our operating plan through at least the end of 2021; with that, operator, please open the line for questions.

Mohit Bansal

analyst
#6

Thanks, and nice work on the momentum. I've got a couple items to raise. First, regarding the TIBSOVO submission in Europe. Can you walk us through whether anything sets TIBSOVO apart from IDHIFA that might give us greater assurance the data behind the TIBSOVO filing is sufficient to clear EMA requirements right now? Then I'll ask a commercial question about PKD.

Chris Bowden

executive
#7

Mohit, Chris Bowden speaking. Appreciate the question; I'd say there are fairly significant distinctions between the enasidenib data set and our strategy and what we're pursuing with TIBSOVO; from the Celgene BMS standpoint, they chose to pull the application after being unable to completely address the MAA and EMA questions. They also have a Phase III trial in relapsed-refractory disease for the indication they're pursuing. So they felt they would pull the application and then revisit their options after the IDHENTIFY readout arrives; that matters quite a bit because the IDH1 mutation's frequency is fairly low across the board. And once you narrow that further within relapsed-refractory disease, one thing we discovered fairly early was that running a randomized trial simply wasn't feasible. So the way we're positioning our case is that this represents the strongest data set obtainable in this rare patient population; consequently, because of the unmet need and the reality that these patients have exhausted everything — they truly lack any remaining treatment choices, we believe our argument there is both distinct and compelling; and there are additional key elements of the submission we're highlighting too; we've managed to access real-world data outcomes from multiple European data centers, and we believe that may prove quite significant for establishing risk benefit. And another element we consider quite significant is that certain data shows IDH1 mutations carry a poor prognosis, and indeed, in the relapsed-refractory setting overall, patients with IDH1 mutation appear to fare worse than those with IDH2 mutation; so that isn't to suggest submitting a non-randomized data set to the European authorities isn't a challenge, but we believe there are meaningful differentiators. That's the reason we're continuing to push ahead and stay optimistic about achieving a positive result. But we'll find out as the process unfolds. And as we've said in prior guidance, the decision isn't expected before the second half of the year.

Mohit Bansal

analyst
#8

Understood. That's quite useful. Now, regarding PKD, Darrin, I believe you said around 1,000 patients have been identified. So first, could you clarify what portion of that is in the U.S. compared with Europe? Also, what obstacles do you foresee in reaching that 3,000 to 8,000-patient figure referenced on your slide?

Darrin Miles

executive
#9

Of course. Of course. It's approximately an even split between the U.S. and outside it, with most of the ex U.S. portion concentrated in EU5. The difficulty, I'd say, with a condition at this far end of the rare disease range is always pinning down the true prevalence figure. That's why we're expanding our field team — to devote more resources toward speeding that up. We've made good progress across the past year-plus. We anticipate a significant acceleration throughout 2020 and then expect to be in a position to potentially document double that count by the time approval arrives at the close of 2021.

Kennen MacKay

analyst
#10

Nice work on the quarter — you folks executed really well. I've got one for Chris first, then something for Jackie and Andrew. Chris, on MDS and the breakthrough tag for TIBSOVO, can you help us get a handle on how the Phase I expansion timing works and whether a registration filing could come out of it? And when might we see that data? Then Jackie and Andrew: I enjoy the Babe Ruth vibe — calling your shot with that $1 billion target for 2025. What's the story behind deciding to share that aspirational number, and can you walk us through how the pieces of it add up?

Chris Bowden

executive
#11

Thanks once more, and congrats. Kennen, Chris here. Right now we're focused on that crucial stage where sites get activated and the amendment gets pushed through, since a lot of the locations that took part in that key 001 trial for us will simply reopen it under the amendment that includes the MDS cohort. That piece matters a great deal to us at the moment. So both the operational side of things and how quickly patients show up, get identified, and enter the study are what will ultimately set the schedule for when data can be released. My impression is that folks have grown fairly at ease with prescribing TIBSOVO for MDS. Still, it's worth keeping in mind that this mutation shows up in only about 1% to 3% of cases. Given that, we feel good about completing enrollment before the year is out. As we draw nearer to that goal — and build greater certainty as the months go by — we'll have a better idea of the timing for releasing and discussing the results, something we're very eager to do.

Jacqualyn Fouse

executive
#12

Kennen, I appreciate you asking that. I actually competed in both fast pitch and slow pitch — I mean, yes, fast pitch and slow pitch softball. So I suppose that comparison works well. So the — looking at the overall vision, which includes at minimum $1 billion of revenue, we — by 2025 — in 2025, we aimed to establish some markers; this isn't just about revenue, but also about the indications we could be — the quantity of programs that will be in the clinic; and the reason we wanted to share that is that we perceive the ability to accomplish those objectives using assets currently in our possession that are either already commercialized. So speaking of TIBSOVO or in the clinic. So by certain definitions of de-risking, these are de-risked assets. When we consider the revenue figure specifically, that incorporates a significant contribution from the continued growth of TIBSOVO in AML. It would also incorporate cholangio, and it would begin to incorporate some revenues in PKD from mitapivat. Most importantly, I believe what it does not incorporate would be thalassemia, sickle cell disease, glioma, since all of those in our assumptions come very late within that 6-year time frame, and we have not assumed anything there for the possibility of negotiating something with Bristol regarding IDHIFA, just to make that extremely, extremely clear.

Alethia Young

analyst
#13

Nice work on what you've accomplished these last couple of months. Since we're tracking this pattern, I've got maybe two things. Could you help us consider how alpha and beta thal differ, and is there any sort of reason to think efficacy would look different in one compared with the other? Then the second one is probably for Jackie. Since a year has passed, I just wanted you to sort of — reflect on how you view where Agios' R&D organization stood a year ago, when you came aboard, versus where you're steering it, and perhaps mix in some thoughts about your potential — your new CSO hire as well?

Chris Bowden

executive
#14

All right. Alethia, this is Chris. I'll start. There's the genotype plus certain molecular distinctions surrounding thalassemia that may matter when it comes to clinical outcomes and possibly a molecular approach. From where we sit, since we're activating wild-type PKR and aiming to boost overall red cell health, we — what I'd say is we'll probably observe — our thinking is there shouldn't be noticeable differences, yet that's among the reasons we're enrolling those patients, and we have a number who have come in now because that question needs an answer. I think the main distinction for thalassemia will likely stay in how we view transfusion-dependent versus not regularly transfused. Those are truly important clinical regulatory pieces. As for the alpha thalassemia part, for us right now it's a point of differentiation, since most of the data — clinical data generated from other molecules out there has been in beta thalassemia, and clinicians have told us this is an important group as well, because they do fall into both of these categories, nontransfusion and transfusion-dependent, and have a high unmet medical need given their underlying disease process.

Jacqualyn Fouse

executive
#15

Alethia, thank you for asking about R&D and our new CSO. Things are in a place that has us really enthusiastic. At a broad level, I'd simply note that out of our approximately 550 staff members, roughly 400 sit within what we refer to as RDS, our research discovery sciences arm, plus our clinical organization. That gives you a sense of the weight we place on both early research and later-stage clinical development, and none of that has shifted. If we look back at Agios's history when it comes to delivering novel science against the diseases we aim to treat, we introduced IDH inhibition into blood cancers and subsequently into solid tumors, and at present we're advancing our PKR activation science together with mitapivat and the next-generation 946 molecule, for which we will submit the IND shortly. Those represent enormous achievements. So regarding this platform in cellular metabolism, the company has absolutely made good on it and will keep making good on it. I believe we're pursuing that in a highly disciplined manner; innovation arrives in waves. Would all of you prefer that we go quicker? Yes, you would. Do we? Yes, we do; we aim for speed with quality; yet that circles back, once more, to the 2025 vision question. A key reason we want to plant stakes in the ground is that we've invested heavily to this point and given where the portfolio stands. I think we're positioned wonderfully to produce remarkable outcomes for patients and strong results for our business model across the coming 6 years. When Scott Biller came aboard nearly 10 years ago — and I believe we expressed our thanks to him during the previous call — a small number of scientists were here, and the RDS team, which Bruce now leads, numbers around 160 to 170 Agios employees internally. I think Scott performed wonderfully. Among his contributions was embedding certain approaches for how we pursue science here, and he assembled an excellent team, and at this point we eagerly anticipate Bruce bringing a new perspective along with the contributions and depth of experience he will add. So I consider it a fairly remarkable feat that we are on the verge of submitting our eighth internally discovered molecule for IND filing, along with everything else we hold. And that vision extending to 2025 involves molecules discovered internally at Agios, and we intend to keep building on our genuine strengths while perhaps concentrating a touch more sharply as we move forward.

Anupam Rama

analyst
#16

I’ve got 2 quick items. Regarding AG-946, what’s your view on the long-term PKR franchise, and could you remind us about any pharmacologic differences between 946 and mitapivat? Also, with thalassemia and sickle cell both coming midyear, how are you approaching the long-term development of 946? Then one quick clarification: the press release was very specific that thalassemia data will be at EHA, while sickle cell was described as midyear, so at this point should we think of the sickle cell update as something outside the conference’s scope?

Chris Bowden

executive
#17

Anupam, this is Chris. Thanks for the questions; we expect, and we should, that the sickle cell data will be presented at EHA. So it’s a double feature, thalassemia and sickle cell. As we’ve said, the sickle cell trial is sponsored through a CRADA agreement with the NIH. So they will be — we will certainly be collaborating with them and providing input, but it is an investigator-sponsored study, if you will. So now, 946 is a particularly interesting clinical development issue for us, because we have a drug in mitapivat that has now been in the clinic for several years, and we gave the community updated data at ASH from DRIVE PK, looking at hemoglobin stability and safety; so now our follow-on molecule AG-946 comes along, and what decisions and how do we think about the next wave of development for that molecule should it pass muster in healthy volunteers and have a safety profile and other aspects that make it a compelling option to move forward into clinical development; so that really means looking across all 3 diseases, and we’ll need to think about that; and then that gets into some of these pharmacological differences you’ve asked me to comment on. So in pyruvate kinase deficiency, the drug may have a broader spectrum of action against some of the mutations that are missense mutations against which mitapivat has not been active. So it could broaden the spectrum of activity. There are some other aspects that we think it may have potential to be once-daily dosing and be a more potent activator of wild-type; so that would then mean once-daily dosing could be a convenience factor across all 3 indications, and a more potent activator of wild-type could translate to some increased efficacy, if — should we — in — whether it’s in thalassemia or sickle cell if we demonstrate proof-of-concept there. What — ultimately, what the steps are and how you develop it as a follow-on, a replacement, what have you, really is way too early to go there; and like we say all the time, it would be a data-driven decision combined with what does mitapivat look like in any of these indications at the given point in time when you start to make some of these decisions, how is the market evolving; so a whole slew of things.

Jacqualyn Fouse

executive
#18

Nice to have options.

Chris Bowden

executive
#19

Yes.

Alexander Duncan

analyst
#20

I just had a quick follow-up question — what are your thoughts about collaborating with the EMA? Given what's happened with the IDHIFA MAA, does that alter how you think about pursuing pipeline development in oncology so that you maximize opportunities outside the U.S.?

Chris Bowden

executive
#21

This is Chris. I'll handle that. I don't believe it does, in the sense that when we brought the IDH inhibitors into the clinic during 2013 and 2014, we immediately saw evidence of clinical benefit in a population with very high unmet need. With both of those molecules, IDHIFA and TIBSOVO, we said so and we moved very fast, because our interactions with the FDA and with investigators across the world showed this was a therapy capable of changing patient outcomes in the relapsed-refractory setting, and that it could dramatically improve clinical benefit for 20% of patients with AML, if you combine IDHIFA and TIBSOVO IDH frequency overall. So those are the fundamental drivers. Do we recognize that taking a non-randomized single-arm data set into other regions of the world means you'll run into some significant challenges, more than what we ran into with our submission to the FDA in the U.S.? Of course we do. We did, long ago, consider very carefully whether we should run a randomized trial in relapsed-refractory IDH1 AML patients, and we examined that question extremely hard, and we concluded it isn't feasible. The greatest impact for patients, and the best use of our resources, lies in the frontline setting; so that's where we focus. And qualitatively, my guess is we would do the very same thing again. And as these opportunities arise, we'll keep operating in this manner.

Hiroshi Shibutani

analyst
#22

Could I pose a couple of questions? First, to get slightly more specific, I appreciate the 2020 guidance for TIBSOVO. Thinking back to last year and the opening quarter, there was perhaps a bit more seasonality on display. My understanding is that's what you reported, and we noticed it in other categories too; by now we're roughly midway through this quarter. Might you weigh in on how we ought to frame the quarter-to-quarter patterns, and specifically, will what we observed a year ago — that seasonality plus the donut hole consequences and so on, along with payer support and patient support programs — persist as a trend through this year? After that, I have a follow-up.

Darrin Miles

executive
#23

Chris, Darrin here. Correct. When we established this year's guidance, our assumption was that a trend comparable to Q1 of last year would emerge. In fact, we've strengthened our patient services support so we can stay ahead of the situation to the greatest extent possible, with particular focus on practices that must follow up with their patients, since those patients may well face a revised or altered set of overall benefits — benefit design and possible cost share, the patient cost burden. So yes, in response to what you asked, we have built in a comparable impact for 2020.

Hiroshi Shibutani

analyst
#24

Excellent; and of course we're eager to see the mitapivat results that will be shared at EHA. Could you remind us, following the data's ASH premiere in thalassemia? My recollection is roughly 8 patients were involved. Can you give us an idea of how many patients there might be, and perhaps what kind of durability we could anticipate once those findings are presented at EHA? Also, might there be some sort of advanced abstract information that could make that result accessible before the meeting takes place?

Chris Bowden

executive
#25

When we write our abstract, our approach will be designed to maximize our odds of securing a slot and being accepted to the meeting. So what specifics will appear in it is something I truly cannot address. Once they're released, it will definitely become available. Enrollment is progressing nicely, and we expect that — we will complete enrollment of 17 patients prior to reaching EHA; and so you'll see extra data, fresh data on alpha thalassemia patients, and then we will definitely be in a position to discuss the overall duration of follow-up, and that should give you an idea of how durable the hemoglobin responses are, how they change as time goes on. So I believe this would truly be the first occasion we're presenting data for mitapivat in thalassemia. So our plan is to offer a fairly comprehensive overview for people from an efficacy, safety and pharmacodynamics perspective since we consider those to all be important readouts.

Mark Breidenbach

analyst
#26

Let me squeeze in 2 quick questions. One is aimed at Chris, and perhaps another one for Darrin too. To start, Chris, I'd love a bit more detail about the folks being enrolled in that NIH sickle cell study. What I'm wondering is whether — and is a pivot being added on top of standard of care treatments, such as hydroxyurea, and might we possibly observe combinations involving Oxbryta within this trial? And beyond that, how would you characterize a successful proof-of-concept when it comes to sickle cell disease?

Chris Bowden

executive
#27

Sure — a patient is allowed to be on Hydrea, and that's definitely part of the eligibility criteria. Drugs such as voxelotor and similar agents would not be allowed, since our goal is genuinely to grasp what mitapivat does and isolate that effect to the greatest extent possible, while also recognizing that certain drugs, Hydrea among them, represent genuine standard of care and matter greatly for patients. Regarding proof-of-concept, I believe the question of which data we'd have to observe before declaring proof-of-concept comes down to a few truly essential elements. Among these is how well patients handled the drug across that 6-week dosing period. What distinctions, if any, can we identify between the smallest dose and the largest dose when it comes to safety? How does exposure appear? And what occurs with oxygen dissociation curves, if anything, across those 3 doses we test? Do we observe any shifts in hemoglobin? And can we successfully tease out, let's say, that dose/exposure related effect? And crucially, can we show in sickle cells a portion of the effects we've managed to show in red cells from patients with pyruvate kinase deficiency or healthy volunteers, or that we've most cleanly used to define our 2,3-DPG and ATP profile changes. Once you move into these patients carrying these various diseases, matters become somewhat more complicated than numero, given the red cell population, and it's somewhat harder to manage than in a healthy volunteer whose red cell compartment is "healthy." So we're also putting a lot of thought into the criteria for demonstrating proof-of-concept, and I believe the other item you ought to be considering, and the way we'll consider it, is what the next steps for development will be. And an earlier question came up: "Would you go — which aspects are you weighing when you conduct additional Phase II work, Phase III work, and so forth?" So all of these will be guided by the totality of data, how many patients we have, and the duration of follow-up too.

Mark Breidenbach

analyst
#28

Okay, that's quite useful. Then one brief additional question for Darrin. Returning to the 1,000 patient — the PKD patient group you've recognized. Could you perhaps share the breakdown within that group between those who depend on transfusions and those who don't; and additionally, whether they've undergone thorough genetic testing to verify that every one of them carries the mutation types that might make them responsive to mitapivat?

Darrin Miles

executive
#29

Mark, unfortunately I don't have those specifics available right now. That's likely something we could circle back on with the — at this stage. What matters most here, I believe, is that our efforts in both the EU and definitely in the U.S. have centered on increasing the urgency surrounding diagnosis, providing assistance for testing, which represents the essential basics we must establish so we can eventually arrive at complete answers to the questions you're posing as well. That said, I believe we could potentially follow up later with additional specifics.

Chris Bowden

executive
#30

Chris speaking. I'd just like to say — there are a few basic points about this disease that, in our view, are essential. One is that 80% of patients carry a missense mutation. That means those individuals could potentially be treated with mitapivat, unlike the 20% who have 2 non-missense mutations. So that's a really key part of how we approach this overall. There are 300 and more mutations that have been described; so the particular genotype, genotype where it's gene A and gene B versus outcomes, that's something we take time to examine. But if you consider how many mutations there are, there's simply a great deal of unknown, unknown in that area.

John Newman

analyst
#31

That's a pretty courageous call on the $1 billion. I have to give you credit for it. I'm just wondering — and I don't believe this is the situation, since it didn't come across that way in what you said beforehand — but is any kind of M&A contemplated within that $1 billion goal? It didn't appear so, yet I figured I would go ahead and ask.

Jacqualyn Fouse

executive
#32

John, this is Jackie. No, nothing related to business development or M&A sits inside that figure. This is what we believe we're capable of delivering at minimum — and I'll say at minimum once more — given what's in front of us right now with TIBSOVO and the portfolio as it stands.

George Farmer

analyst
#33

I want to understand this better, and maybe you can take it, Darrin. It concerns how much TIBSOVO is getting into the AML setting alongside HMAs, and you're now seeing more uptake in that combo context. In combination with HMA, how are physicians weighing alternating TIBSOVO and venetoclax?

Darrin Miles

executive
#34

Let me start by establishing a couple of points fully. Our research keeps showing a strong conviction about the significance of hitting the target. What I mean is, when a targeted therapy exists for a mutation that can be identified, doctors lean toward prescribing it. What matters alongside that, I believe, is a similarly strong conviction that IDH1 — mutated IDH1 — serves as the driver mutation here, especially as the early driver mutation. That, together with the clinical outcomes data, is what propels uptake of TIBSOVO, as a single agent and in combination in the frontline setting, even though our promotion covers only single-agent use. The data we've observed, improving each quarter relative to the last, points to it being the regimen most preferred — roughly 50% of all use, in frontline as well as relapse, happens in combination with HMAs. Once more, we don't promote it. Still, this usage probably stems from greater familiarity with the combination data we've updated at the congress across the last 2 years, and most recently at ASH. Regarding how they'll alternate between venetoclax and TIBSOVO, ultimately our frontline focus, at least for the monotherapy indication, centers on patients who've had prior exposure to an HMA. I believe we achieve — that message resonates well with the community there. Then, as awareness grows around the emerging combination data, they find the overall clinical profile compelling, which pushes them to widen use past that segment of the patient population. So — and at this point, I'd say it remains fairly early days while the community works out what their established treatment algorithms will be, given the wave of new treatments arriving in frontline as well as relapse.

George Farmer

analyst
#35

Great. That's really useful. Then when it comes to mitapivat, what's the right way to think about how the drug works against the mutated version of the enzyme compared with the wild-type version? Are there subtle distinctions? And should we worry about hemoglobin going too high? I believe that was a problem during earlier development. And does genotype play a role there, in your view?

Chris Bowden

executive
#36

Yes. This is Chris. Genotype does matter in pyruvate kinase deficiency, since protein has to be present for the drug to bind, and we've observed that non-missense mutations tend to be less stable, with not as much protein available — there's nowhere for the drug to attach because a large deletion has occurred; so genotype and molecular features are truly important when it comes to pyruvate kinase deficiency and the capacity to activate the enzyme. In thalassemia and sickle cell, we aim to activate the wild-type enzyme, the very same pyruvate kinase found in anyone's red cells absent an underlying hemoglobinopathy or absent pyruvate kinase deficiency; now something potentially interesting is whether outcomes, when wild-type PKR is activated, will depend on, say, which type of thalassemia? Whether it's alpha or beta or the different globinopathies that can appear within that disease, or in sickle cell, whether you're SS or have S-thal? Those are things we'll be examining. So we generally view these 3 diseases as distinct. We do — you'll hear us group thalassemia and sickle cell together to some degree, because our approach is activating wild-type PKR, while in pyruvate kinase deficiency, we're activating the mutant form of the disease; so with pyruvate kinase deficiency, there's less ATP owing to that mutated enzyme, while in these wild-type approaches there's a relatively — I wouldn't call it normal, but there's more ATP present and we're trying to raise the ATP level so those red cells can handle their underlying disease process and survive longer.

Jacqualyn Fouse

executive
#37

Thanks, operator. For Agios, 2020 stands out as a decisive year, since we're carrying out key milestones throughout our business. Across all 3 of our therapeutic focus areas, we anticipate meaningful advancement in our clinical pipeline, along with remarkable expansion in product revenues and ongoing output from our research engine, including a new IND slated for filing during this quarter. To every one of the incredible Agios employees, I want to express my gratitude for your commitment and enthusiasm in striving to improve patients' lives. My thanks also go out to each patient, caregiver and physician taking part in our clinical trials. Absent their involvement, today's work would be impossible. Finally, I'd like to thank each of you for being with us on today's call, and we'll be in touch again before long.

Operator

operator
#38

That brings us to the end, everyone, and we appreciate your joining us. At this point, you're free to hang up.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.